I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC
Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.
cancer chemotherapy
metastasis
non-small cell lung cancer
RET
pralsetinib
- 0 views
- 16 Feb, 2024
- 1 location